Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
VICTORIA, BC, May 22, 2024 -?Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere? technology to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, May 29, 2024, at 10:00 AM ET.
To register, please click here.
The event will feature Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) who will join Company management to discuss the unmet medical need and current treatment landscape for EoE. Dr. Dellon is Chairman of the Company's Gastrointestinal Clinical Advisory Board.
The KOL event will focus on data from the Phase 1b/2a RESOLVE clinical trial and highlight clinical development plans evaluating EP-104GI for the treatment of EoE.
Utilizing the Company's proprietary DiffuSphere? technology, EP-104GI has shown the potential to target drug delivery to the esophageal tissue and improve treatment outcomes for the EoE patient population.
A live question-and-answer session will follow the formal presentation.